Surmodics, Inc. announced it has been awarded a group purchasing agreement for thrombectomy products with Premier, Inc. Effective June 1, 2024, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Surmodics Pounce?? and Pounce?? Venous Thrombectomy Systems. The Surmodics thrombectomy portfolio comprises fully mechanical, non-aspiration endovascular systems designed to rapidly remove soft or hardened blood clots from peripheral arteries (Pounce Thrombectomy and Pounce Low-Profile [LP] Thrombectomy Systems) or peripheral veins (Pounce Venous Thrombectomy System).

Surmodics thromssectomy systems, which do not require capital equipment, are designed to minimize the need for physicians to remove clots using thrombolytic drugs, a treatment that typically requires overnight admission to an intensive care unit. Premier is a leading healthcare improvement company, uniting an alliance of more than 4,350 U.S. hospitals and 300,000 other providers to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and advisory and other services, Premier enables better care and outcomes at a lower cost.